Following Vinay Prasad’s second and presumably final departure from his job as director of the Center for Biologics Evaluation and Research, Prasad’s deputy Katherine Szarama has stepped in as acting drector.
AstraZeneca’s application for camizestrant, a next-generation oral selective estrogen receptor degrader, or SERD, in metastatic breast cancer might have seemed set to sail smoothly through the FDA approval process.
